Evaluation of the behavior of platelets count, EGF serum concentrations and the levels of lymphocytes subpopulations expression associated with the patient's immune status as possible biomarkers of effectiveness of CIMAvax-EGF vaccine.
Phase of Trial: Phase II
Latest Information Update: 13 Nov 2018
At a glance
- Drugs BV NSCLC 001 (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 13 Nov 2018 New trial record